ImmunoPrecise Antibodies jumps on AI-powered diabetes treatment

Mindwalk Holdings

22/01/2025 17:59

** Shares of biotech firm ImmunoPrecise Antibodies  IPA.O  rise
~42% to 69 cents
** IPA says it has developed a new class of GLP-1 therapies
using AI to improve diabetes treatment
    ** IPA's proprietary tech, called LENSai, uses patterns in
biological data to create novel genetic sequences for GLP-1-like
constructs
    ** Co says it is investigating transdermal delivery of these
therapies as a non-invasive alternative to injections
    ** More than 300 mln shares traded, 708x times their 25-day
moving avg
    ** IPA fell ~76% in 2024

(Reporting by Kamal Choudhury in Bengaluru)
((mailto:Kamal.Choudhury@thomsonreuters.com))